Inherited pancreatic cancer.

Pancreatic cancers arise through a series of genetic events both inherited and acquired. Inherited genetic changes, both high penetrance and low penetrance, are an important component of pancreatic cancer risk, and may be used to characterize populations who will benefit from early detection. Furthermore, pancreatic cancer patients with inherited mutations may be particularly sensitive to certain targeted agents, providing an opportunity to personalized treatment. Family history of pancreatic cancer is one of the strongest risk factors for the disease, and is associated with an increased risk of caners at other sites, including but not limited to breast, ovarian and colorectal cancer. The goal of this chapter is to discuss the importance of family history of pancreatic cancer, and the known genes that account for a portion of the familial clustering of pancreatic cancer.

[1]  P. Duijf,et al.  Silencing of BACH1 inhibits invasion and migration of prostate cancer cells by altering metastasis-related gene expression , 2018, Artificial cells, nanomedicine, and biotechnology.

[2]  B. Győrffy,et al.  linc00673 (ERRLR01) is a prognostic indicator of overall survival in breast cancer , 2018, Transcription.

[3]  Aung Ko Win,et al.  Genome‐wide association study and meta‐analysis in Northern European populations replicate multiple colorectal cancer risk loci , 2017, International journal of cancer.

[4]  Richard J. Wenstrup,et al.  PREVALENCE OF GERMLINE MUTATIONS IN CANCER GENES AMONG PANCREATIC CANCER PATIENTS WITH POSITIVE FAMILY HISTORY , 2017, Genetics in Medicine.

[5]  Ken R. Smith,et al.  Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome , 2017, JAMA oncology.

[6]  M. Park,et al.  FAM19A5, a brain-specific chemokine, inhibits RANKL-induced osteoclast formation through formyl peptide receptor 2 , 2017, Scientific Reports.

[7]  E. Schröck,et al.  ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage. , 2017, Cancer research.

[8]  M. Nagino,et al.  Trefoil factor family 1 expression in the invasion front is a poor prognostic factor associated with lymph node metastasis in pancreatic cancer. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[9]  Masaya Suenaga,et al.  Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Han Wu,et al.  Long non-coding RNA linc00673 regulated non-small cell lung cancer proliferation, migration, invasion and epithelial mesenchymal transition by sponging miR-150-5p , 2017, Molecular Cancer.

[11]  E. Kopantzev,et al.  Expression of transcription factor genes in cell lines corresponding to different stages of pancreatic cancer progression , 2017, Doklady Biochemistry and Biophysics.

[12]  E. Kopantzev,et al.  Expression of master regulatory genes of embryonic development in pancreatic tumors , 2017, Doklady Biochemistry and Biophysics.

[13]  P. Møller,et al.  Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database , 2017, Gut.

[14]  Huamin Wang,et al.  Effect of NR5A2 inhibition on pancreatic cancer stem cell (CSC) properties and epithelial‐mesenchymal transition (EMT) markers , 2017, Molecular carcinogenesis.

[15]  Qingqing Zhu,et al.  Long intergenic noncoding RNA 00673 promotes non-small-cell lung cancer metastasis by binding with EZH2 and causing epigenetic silencing of HOXA5 , 2017, Oncotarget.

[16]  Z. Zeng,et al.  Overexpression long non-coding RNA LINC00673 is associated with poor prognosis and promotes invasion and metastasis in tongue squamous cell carcinoma , 2016, Oncotarget.

[17]  J. Lubiński,et al.  The Prevalence of Founder Mutations among Individuals from Families with Familial Pancreatic Cancer Syndrome , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[18]  A. Masamune,et al.  Nationwide survey of hereditary pancreatitis in Japan , 2017, Journal of Gastroenterology.

[19]  D. Gudbjartsson,et al.  A common variant at 8q24.21 is associated with renal cell cancer , 2013, Nature Communications.

[20]  B. Baradaran,et al.  BACH1 silencing by siRNA inhibits migration of HT-29 colon cancer cells through reduction of metastasis-related genes. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[21]  K. Klein,et al.  Association between family cancer history and risk of pancreatic cancer. , 2016, Cancer epidemiology.

[22]  J. Manson,et al.  Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer , 2016, Gut.

[23]  S. Yachida,et al.  Germline mutations in Japanese familial pancreatic cancer patients , 2016, Oncotarget.

[24]  Alison P. Klein,et al.  Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21 , 2016, Oncotarget.

[25]  Wen Tan,et al.  Pancreatic cancer risk variant in LINC00673 creates a miR-1231 binding site and interferes with PTPN11 degradation , 2016, Nature Genetics.

[26]  Y. Ye,et al.  Cancer Incidence in First- and Second-Degree Relatives of BRCA1 and BRCA2 Mutation Carriers. , 2016, The oncologist.

[27]  P. Souček,et al.  Mutation analysis of the PALB2 gene in unselected pancreatic cancer patients in the Czech Republic. , 2016, Cancer genetics.

[28]  V. Ellenrieder,et al.  MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies , 2016, Oncogene.

[29]  Xuefei Shi,et al.  Upregulation of long intergenic noncoding RNA 00673 promotes tumor proliferation via LSD1 interaction and repression of NCALD in non-small-cell lung cancer , 2016, Oncotarget.

[30]  G. Natoli,et al.  Dissection of transcriptional and cis‐regulatory control of differentiation in human pancreatic cancer , 2016, The EMBO journal.

[31]  J. Potash,et al.  Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. , 2016, Cancer discovery.

[32]  Ning Wang,et al.  Risk Factors for Pancreatic Cancer in China: A Multicenter Case-Control Study , 2015, Journal of epidemiology.

[33]  Prasenjit Dey,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[34]  Han Liu,et al.  KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells , 2016, Tumor Biology.

[35]  N. Petrelli,et al.  Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds , 2016, Annals of Surgical Oncology.

[36]  K. Offit,et al.  Identification of germline genetic mutations in patients with pancreatic cancer , 2015, Cancer.

[37]  Yurii B. Shvetsov,et al.  Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. , 2015, Carcinogenesis.

[38]  N. Funel,et al.  TERT gene harbors multiple variants associated with pancreatic cancer susceptibility , 2015, International journal of cancer.

[39]  P. Souček,et al.  Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma , 2015, PloS one.

[40]  Raymond M. Moore,et al.  Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[41]  Yongping Cui,et al.  Loss of KLF14 triggers centrosome amplification and tumorigenesis , 2015, Nature Communications.

[42]  B. Dai,et al.  CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. , 2015, International journal of clinical and experimental medicine.

[43]  Mengmeng Zhang,et al.  Disabled homolog 2 is required for migration and invasion of prostate cancer cells , 2015, Frontiers of Medicine.

[44]  T. Jin,et al.  Polymorphisms of PRLHR and HSPA12A and risk of gastric and colorectal cancer in the Chinese Han population , 2015, BMC Gastroenterology.

[45]  Ping Sun,et al.  CHEK2 mutations and the risk of papillary thyroid cancer , 2015, International journal of cancer.

[46]  Raffaele Pezzilli,et al.  Common variation at 2 p 13 . 3 , 3 q 29 , 7 p 13 and 17 q 25 . 1 associated with susceptibility to pancreatic cancer , 2022 .

[47]  D. Hedley,et al.  Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  Wei Wang,et al.  Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. , 2015, European journal of cancer.

[49]  G. Petersen,et al.  Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. , 2015, Gastroenterology.

[50]  S. Kalghatgi,et al.  Pancreatic Cancer in Chronic Pancreatitis , 2015, Indian Journal of Surgical Oncology.

[51]  Ayala Hubert,et al.  Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[53]  Michele L Cote,et al.  BRCA1, BRCA2, PALB2, and CDKN2A Mutations in Familial Pancreatic Cancer (FPC): A PACGENE Study , 2014, Genetics in Medicine.

[54]  D. Barge-Schaapveld,et al.  Prospective risk of cancer and the influence of tobacco use in carriers of the p16-Leiden germline variant , 2014, European Journal of Human Genetics.

[55]  D. Delia,et al.  Chk2 and REGγ-dependent DBC1 regulation in DNA damage induced apoptosis , 2014, Nucleic acids research.

[56]  Yusuke Nakamura,et al.  Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer , 2014, Nature Genetics.

[57]  S. Gallinger,et al.  The Association of Family History of Cancer and Medical History With Pancreatic Cancer Risk , 2014, Pancreas.

[58]  Hebin Wang,et al.  Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. , 2014, Cancer letters.

[59]  A. Gaponova,et al.  CAS proteins in health and disease: An update , 2014, IUBMB life.

[60]  Laura H. Tang,et al.  Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). , 2014 .

[61]  S. Thorgeirsson,et al.  CLPTM1L promotes growth and enhances aneuploidy in pancreatic cancer cells. , 2014, Cancer research.

[62]  D. Hu,et al.  Association of KCNQ1 and KLF14 polymorphisms and risk of type 2 diabetes mellitus: A global meta-analysis. , 2014, Human immunology.

[63]  M. You,et al.  Crr9/clptm1l Regulates Cell Survival Signaling and Is Required for Ras Transformation and Lung Tumorigenesis Figures: 7 Main Text and 7 Supplementary , 2022 .

[64]  H. Risch,et al.  Re-evaluation of ABO gene polymorphisms detected in a genome-wide association study and risk of pancreatic ductal adenocarcinoma in a Chinese population , 2014, Chinese journal of cancer.

[65]  J. Minna,et al.  miR-93-directed down-regulation of DAB2 defines a novel oncogenic pathway in lung cancer , 2013, Oncogene.

[66]  Xuemei Xie,et al.  Frequent Loss Expression of Dab2 and Promotor Hypermethylation in Human Cancers: A Meta-Analysis and Systematic Review , 1969, Pakistan journal of medical sciences.

[67]  D. Gudbjartsson,et al.  A common variant at 8q24.21 is associated with renal cell cancer , 2013, Nature Communications.

[68]  J. Potter,et al.  Family History of Diabetes and Pancreatic Cancer as Risk Factors for Pancreatic Cancer: The PACIFIC Study , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[69]  T. Hansen,et al.  The CTRB1/2 Locus Affects Diabetes Susceptibility and Treatment via the Incretin Pathway , 2013, Diabetes.

[70]  L. Aaltonen,et al.  Lessons from functional analysis of genome-wide association studies. , 2013, Cancer research.

[71]  A. Andriulli,et al.  Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study. , 2013, Digestive and Liver Disease.

[72]  H. Risch,et al.  ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. , 2013, American journal of epidemiology.

[73]  A. Paradiso,et al.  Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity , 2013, Molecular oncology.

[74]  C. Wright,et al.  Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation , 2013, Gut.

[75]  F. Real,et al.  Nr5a2 heterozygosity sensitises to, and cooperates with, inflammation in KRasG12V-driven pancreatic tumourigenesis , 2013, Gut.

[76]  P. Frankel,et al.  p130Cas: a key signalling node in health and disease. , 2013, Cellular signalling.

[77]  J. Hoheisel,et al.  ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. , 2013, Oncology reports.

[78]  Wei Lu,et al.  Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer , 2013, Nature Genetics.

[79]  H. Rui,et al.  Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer. , 2013, Cancer research.

[80]  T. Hansen,et al.  Type 2 diabetes risk alleles near BCAR1 and in ANK1 associate with decreased β-cell function whereas risk alleles near ANKRD55 and GRB14 associate with decreased insulin sensitivity in the Danish Inter99 cohort. , 2013, The Journal of clinical endocrinology and metabolism.

[81]  N. Malats,et al.  Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry , 2013, Cancer Epidemiology, Biomarkers & Prevention.

[82]  J. Marshall,et al.  A phase I/II study of ABT-888 in combination with 5-fluorouracil (5-FU) and oxaliplatin (Ox) in patients with metastatic pancreatic cancer (MPC). , 2013 .

[83]  A. Klein.  Identifying people at a high risk of developing pancreatic cancer , 2012, Nature Reviews Cancer.

[84]  Kun Tao,et al.  CLPTM1L Is Overexpressed in Lung Cancer and Associated with Apoptosis , 2012, PloS one.

[85]  E. Kuipers,et al.  Pancreatic cancer risk in Peutz-Jeghers syndrome patients: a large cohort study and implications for surveillance , 2012, Journal of Medical Genetics.

[86]  Paul Fockens,et al.  International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer , 2012, Gut.

[87]  S. Kung,et al.  Transcriptional Network Analysis Identifies BACH1 as a Master Regulator of Breast Cancer Bone Metastasis , 2012, The Journal of Biological Chemistry.

[88]  Tanya M. Teslovich,et al.  Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes , 2012, Nature Genetics.

[89]  Geoffrey S. Tobias,et al.  Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. , 2012, Carcinogenesis.

[90]  C. Amos,et al.  Cancer spectrum in DNA mismatch repair gene mutation carriers: results from a hospital based Lynch syndrome registry , 2012, Familial Cancer.

[91]  R. Millikan,et al.  Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers. , 2012, Journal of the National Cancer Institute.

[92]  R. Klein,et al.  A Replication Study and Genome-Wide Scan of Single-Nucleotide Polymorphisms Associated with Pancreatic Cancer Risk and Overall Survival , 2012, Clinical Cancer Research.

[93]  K. Coombes,et al.  Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus , 2012, PloS one.

[94]  H. Ruffner,et al.  ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner , 2012, Nature.

[95]  Aung Ko Win,et al.  Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[96]  Y. Gho,et al.  Dab2 is pivotal for endothelial cell migration by mediating VEGF expression in cancer cells. , 2012, Experimental cell research.

[97]  Wen Tan,et al.  Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations , 2011, Nature Genetics.

[98]  Yuchen Jiao,et al.  ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.

[99]  V. Pensotti,et al.  Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy , 2012, Familial Cancer.

[100]  M. Korc,et al.  Correction: DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance , 2018, PloS one.

[101]  R. Hwang,et al.  Trefoil Factor 1 Stimulates Both Pancreatic Cancer and Stellate Cells and Increases Metastasis , 2011, Pancreas.

[102]  G. Melino.  p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53 , 2011, Cell Death and Differentiation.

[103]  D. Birnbaum,et al.  Genome profiling of pancreatic adenocarcinoma , 2011, Genes, chromosomes & cancer.

[104]  K. Matsuo,et al.  ABO blood group alleles and the risk of pancreatic cancer in a Japanese population , 2011, Cancer science.

[105]  Mark I. McCarthy,et al.  Identification of an imprinted master trans-regulator at the KLF14 locus related to multiple metabolic phenotypes , 2011, Nature Genetics.

[106]  Michael R Bardsley,et al.  A functional family-wide screening of SP/KLF proteins identifies a subset of suppressors of KRAS-mediated cell growth. , 2011, The Biochemical journal.

[107]  Xiao-Fan Wang,et al.  Trefoil factor 1 acts to suppress senescence induced by oncogene activation during the cellular transformation process , 2011, Proceedings of the National Academy of Sciences.

[108]  Kenneth Offit,et al.  Germline PALB2 mutation analysis in breast–pancreas cancer families , 2011, Journal of Medical Genetics.

[109]  P. Miron,et al.  PALB2 mutations in familial breast and pancreatic cancer , 2011, Familial Cancer.

[110]  J. Stockman,et al.  Risk of Pancreatic Cancer in Families With Lynch Syndrome , 2011 .

[111]  P. Radice,et al.  PALB2 germline mutations in familial breast cancer cases with personal and family history of pancreatic cancer , 2011, Breast Cancer Research and Treatment.

[112]  Manuel Hidalgo,et al.  Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer , 2010, Molecular Cancer Therapeutics.

[113]  K. Strauch,et al.  PALB2 mutations in European familial pancreatic cancer families , 2010, Clinical genetics.

[114]  A. Whittemore,et al.  A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24 , 2010, Nature Genetics.

[115]  Geoffrey S. Tobias,et al.  Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan) , 2010, International journal of cancer.

[116]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[117]  Yusuke Nakamura,et al.  Genome-Wide Association Study of Pancreatic Cancer in Japanese Population , 2010, PloS one.

[118]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[119]  Ayellet V. Segrè,et al.  Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis , 2010, Nature Genetics.

[120]  P. Maisonneuve,et al.  Pancreatic cancer in chronic pancreatitis; aetiology, incidence, and early detection. , 2010, Best practice & research. Clinical gastroenterology.

[121]  E. Kuipers,et al.  High Cancer Risk in Peutz–Jeghers Syndrome: A Systematic Review and Surveillance Recommendations , 2010, The American Journal of Gastroenterology.

[122]  Wei Zheng,et al.  A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33 , 2010, Nature Genetics.

[123]  S. Hahn,et al.  Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families , 2010, Familial Cancer.

[124]  Geoffrey S. Tobias,et al.  Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. , 2010, Cancer research.

[125]  B. Lau,et al.  Importance of Age of Onset in Pancreatic Cancer Kindreds , 2010, Journal of the National Cancer Institute.

[126]  D. Clayton,et al.  Genome-wide association study and meta-analysis finds over 40 loci affect risk of type 1 diabetes , 2009, Nature Genetics.

[127]  J. Cameron,et al.  Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer , 2009, Cancer Epidemiology, Biomarkers & Prevention.

[128]  K. Hemminki,et al.  Familial association of pancreatic cancer with other malignancies in Swedish families , 2009, British Journal of Cancer.

[129]  W. Foulkes,et al.  Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. , 2009, Gastroenterology.

[130]  Geoffrey S. Tobias,et al.  Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer , 2009, Nature Genetics.

[131]  O. Stoeltzing,et al.  Up-Regulation of Krüppel-Like Factor 5 in Pancreatic Cancer Is Promoted by Interleukin-1β Signaling and Hypoxia-Inducible Factor-1α , 2009, Molecular Cancer Research.

[132]  M. Thun,et al.  Family history of various cancers and pancreatic cancer mortality in a large cohort , 2009, Cancer Causes & Control.

[133]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[134]  S. Chanock,et al.  ABO blood group and the risk of pancreatic cancer. , 2009, Journal of the National Cancer Institute.

[135]  E. Puffenberger,et al.  Genetic mapping of glutaric aciduria, type 3, to chromosome 7 and identification of mutations in c7orf10. , 2008, American journal of human genetics.

[136]  D. Bishop,et al.  Increased Risk of Cancer Other Than Melanoma in CDKN2A Founder Mutation (p16-Leiden)-Positive Melanoma Families , 2008, Clinical Cancer Research.

[137]  H. Morgenstern,et al.  Associations between Variants of the 8q24 Chromosome and Nine Smoking-Related Cancer Sites , 2008, Cancer Epidemiology Biomarkers & Prevention.

[138]  P. Ruszniewski,et al.  Risk of Pancreatic Adenocarcinoma in Patients With Hereditary Pancreatitis: A National Exhaustive Series , 2008, The American Journal of Gastroenterology.

[139]  Kathleen M. Egan,et al.  Family history is a significant risk factor for pancreatic cancer: results from a systematic review and meta-analysis , 2008, Familial Cancer.

[140]  S. Seal,et al.  PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene , 2007, Nature Genetics.

[141]  Mariza de Andrade,et al.  The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[142]  John J. Davis,et al.  Combination therapy of poly (ADP‐ribose) polymerase inhibitor 3‐aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cells , 2006, Journal of gastroenterology and hepatology.

[143]  J. Greenson,et al.  Risk of Other Cancers in Individuals with a Family History of Pancreas Cancer , 2007, Journal of gastrointestinal cancer.

[144]  R. Eeles,et al.  Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC) , 2007, Familial Cancer.

[145]  D. Whitcomb,et al.  Human Pancreatic Digestive Enzymes , 2007, Digestive Diseases and Sciences.

[146]  Barry Rosen,et al.  Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. , 2006, Journal of the National Cancer Institute.

[147]  H. Nevanlinna,et al.  The CHEK2 gene and inherited breast cancer susceptibility , 2006, Oncogene.

[148]  Y. Ikawa,et al.  p51/p63, a novel p53 homologue, potentiates p53 activity and is a human cancer gene therapy candidate , 2006, The journal of gene medicine.

[149]  S. Gruber,et al.  Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome , 2006, Clinical Cancer Research.

[150]  R. DePinho,et al.  Genetics and biology of pancreatic ductal adenocarcinoma , 2006, Genes & development.

[151]  R. Hruban,et al.  In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor , 2005, Clinical Cancer Research.

[152]  J. C. Houwelingen,et al.  Cancer risks in BRCA2 families: estimates for sites other than breast and ovary , 2005, Journal of Medical Genetics.

[153]  A. Ashworth,et al.  BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency , 2005, Cancer biology & therapy.

[154]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[155]  A. Yang,et al.  Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. , 2005, Cancer cell.

[156]  Michael Goggins,et al.  Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. , 2005, Cancer research.

[157]  R. Hruban,et al.  Functional defects in the fanconi anemia pathway in pancreatic cancer cells. , 2004, The American journal of pathology.

[158]  J. Struewing,et al.  Prospective risk of cancer in CDKN2A germline mutation carriers , 2004, Journal of Medical Genetics.

[159]  K. Hemminki,et al.  Familial association of histology specific breast cancers with cancers at other sites , 2004, International journal of cancer.

[160]  Alison P. Klein,et al.  Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds , 2004, Cancer Research.

[161]  W. Greenhalf,et al.  Clinical and genetic characteristics of hereditary pancreatitis in Europe. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[162]  K. Hemminki,et al.  Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden , 2003, Gut.

[163]  K. Hemminki,et al.  Familial and second primary pancreatic cancers: A nationwide epidemiologic study from Sweden , 2003, International journal of cancer.

[164]  A. Ziegler,et al.  BRCA2 germline mutations in familial pancreatic carcinoma. , 2003, Journal of the National Cancer Institute.

[165]  A. Tsur,et al.  Pancreatic Duodenal Homeobox (PDX-1) in Health and Disease , 2002, Journal of pediatric endocrinology & metabolism : JPEM.

[166]  Scott E Kern,et al.  Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. , 2002, The American journal of pathology.

[167]  Y. Jan,et al.  Characterisation of oestrogen receptor, progesterone receptor, trefoil factor 1, and epidermal growth factor and its receptor in pancreatic cystic neoplasms and pancreatic ductal adenocarcinoma , 2002, Gut.

[168]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[169]  T. Beaty,et al.  Evidence for a major gene influencing risk of pancreatic cancer , 2002, Genetic epidemiology.

[170]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[171]  Tatjana Crnogorac-Jurcevic,et al.  Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. , 2002, The American journal of pathology.

[172]  C. Tseng,et al.  The Mechanism of Growth-inhibitory Effect of DOC-2/DAB2 in Prostate Cancer , 2002, The Journal of Biological Chemistry.

[173]  H. Zentgraf,et al.  c-MYC Activation in Primary and Metastatic Ductal Adenocarcinoma of the Pancreas: Incidence, Mechanisms, and Clinical Significance , 2002, Modern Pathology.

[174]  K. Docherty,et al.  Pancreatic duodenal homeobox–1, PDX-1, a major regulator of beta cell identity and function , 2001, Diabetologia.

[175]  M. Lerch,et al.  Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. , 2001, JAMA.

[176]  K. Wakasa,et al.  Expression of p73 and p63 proteins in pancreatic adenocarcinoma: p73 overexpression is inversely correlated with biological aggressiveness. , 2001, International journal of molecular medicine.

[177]  G. Ying,et al.  Familial risk of pancreatic cancer. , 2001, Journal of the National Cancer Institute.

[178]  S. Goodman,et al.  Very high risk of cancer in familial Peutz-Jeghers syndrome. , 2000, Gastroenterology.

[179]  J. Kaprio,et al.  Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. , 2000, The New England journal of medicine.

[180]  Kerstin,et al.  High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. , 2000, Journal of the National Cancer Institute.

[181]  P. Bruzzi,et al.  Characterization of ligurian melanoma families and risk of occurrence of other neoplasia , 1999, International journal of cancer.

[182]  K. Lillemoe,et al.  Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer , 1999, British Journal of Cancer.

[183]  L. Aaltonen,et al.  Cancer risk in mutation carriers of DNA‐mismatch‐repair genes , 1999, International journal of cancer.

[184]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[185]  Josephine C. Adams,et al.  Muskelin, a novel intracellular mediator of cell adhesive and cytoskeletal responses to thrombospondin‐1 , 1998, The EMBO journal.

[186]  H. Edlund,et al.  beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. , 1998, Genes & development.

[187]  M. Stratton,et al.  A serine/threonine kinase gene defective in Peutz–Jeghers syndrome , 1998, Nature.

[188]  J. Nezu,et al.  Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. , 1998, Nature genetics.

[189]  R H Hruban,et al.  Genetics of pancreatic cancer. From genes to families. , 1998, Surgical oncology clinics of North America.

[190]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[191]  Darryl Shibata,et al.  Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis , 1997, Nature Genetics.

[192]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[193]  B. Hogan,et al.  PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. , 1996, Development.

[194]  A M Goldstein,et al.  Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. , 1995, The New England journal of medicine.

[195]  C. la Vecchia,et al.  Family history and the risk of liver, gallbladder, and pancreatic cancer. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[196]  H. Lynch,et al.  Extracolonic cancer in hereditary nonpolyposis colorectal cancer. , 1993, Cancer.

[197]  J. Baillargeon,et al.  Cancer of the pancreas in two brothers and one sister , 1987, International journal of pancreatology : official journal of the International Association of Pancreatology.

[198]  T. Griffin,et al.  Familial pancreatic adenocarcinoma in three generations. A case report and a review of the literature , 1987, Cancer.

[199]  S. Sontag,et al.  Pancreatic carcinoma in brothers. , 1982, Annals of internal medicine.

[200]  P. Fialkow,et al.  Familial carcinoma of the pancreas * , 1976, Clinical genetics.

[201]  R. Macdermott,et al.  Adenocarcinoma of the pancreas in four siblings. , 1973, Gastroenterology.